PROPANC BIOPHARMA, INC. Adjustments to Additional Paid in Capital, Other
PROPANC BIOPHARMA, INC. (PPCB) reported Adjustments to Additional Paid in Capital, Other of $114.40 thousand for the 3-month period ending 2025-09-30, per its S-1 filed 2026-07-17.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalOther · last filed 2026-07-17
- PROPANC BIOPHARMA, INC. adjustments to additional paid in capital, other for the quarter ending 2025-09-30 was $114.40K.
- PROPANC BIOPHARMA, INC. adjustments to additional paid in capital, other for the quarter ending 2022-09-30 was $5.55K.
- PROPANC BIOPHARMA, INC. adjustments to additional paid in capital, other for the quarter ending 2019-09-30 was $73.23K, a 87.80% decline year-over-year.
- PROPANC BIOPHARMA, INC. adjustments to additional paid in capital, other for the quarter ending 2018-12-31 was $708.18K, a 238.68% increase year-over-year.
- PROPANC BIOPHARMA, INC. adjustments to additional paid in capital, other for fiscal 2023 was $5.55K.
- PROPANC BIOPHARMA, INC. adjustments to additional paid in capital, other for fiscal 2019 was $1.82M, a 92.41% increase from fiscal 2018.
- PROPANC BIOPHARMA, INC. adjustments to additional paid in capital, other for fiscal 2018 was $948.13K, a 256.06% increase from fiscal 2017.
- PROPANC BIOPHARMA, INC. adjustments to additional paid in capital, other for fiscal 2017 was $266.29K, a 78.75% decline from fiscal 2016.
| Period end | Adjustments to Additional Paid in Capital, Other 3 month | Adjustments to Additional Paid in Capital, Other 3 month as first filed | Adjustments to Additional Paid in Capital, Other 6 month | Adjustments to Additional Paid in Capital, Other 9 month | Adjustments to Additional Paid in Capital, Other 12 month |
|---|---|---|---|---|---|
| 2025-09-30 | $114.40K S-1 · filed 2026-07-17 | ||||
| 2023-06-30 | $5.55K 10-K · filed 2024-09-30 | ||||
| 2022-09-30 | $5.55K 10-Q · filed 2024-05-15 | $2.41K 10-Q · filed 2022-11-14 | |||
| 2019-09-30 | $73.23K 10-Q · filed 2019-11-14 | ||||
| 2019-06-30 | $1.82M 10-K · filed 2019-10-15 | ||||
| 2018-12-31 | $708.18K 10-Q · filed 2019-05-15 | $1.31M derived: sum of 2 quarters · filed 2019-11-14 | |||
| 2018-09-30 | $600.21K 10-Q · filed 2019-11-14 | ||||
| 2018-06-30 | $948.13K 10-K · filed 2019-10-15 | ||||
| 2018-03-31 | $341.37K 10-Q · filed 2019-05-15 | $550.47K derived: sum of 2 quarters · filed 2019-05-15 | $678.81K derived: sum of 3 quarters · filed 2019-05-15 | ||
| 2017-12-31 | $209.10K 10-Q · filed 2019-05-15 | $337.44K derived: sum of 2 quarters · filed 2019-05-15 | |||
| 2017-09-30 | $128.33K 10-Q · filed 2019-05-15 | ||||
| 2017-06-30 | $266.29K 10-K · filed 2018-09-17 | ||||
| 2016-06-30 | $1.25M 10-K · filed 2017-09-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CHINA PHARMA HOLDINGS, INC. (CPHI) | $0.032B | ||
| NANOVIRICIDES, INC. (NNVC) | United States | $0.031B | |
| BeyondSpring Inc. (BYSI) | United States | $0.031B | -10.95 |
| Context Therapeutics Inc. (CNTX) | United States | $0.034B | -1.10 |
| ROCKWELL MEDICAL, INC. (RMTI) | United States | $0.035B | |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |